Skip to main content
Caplight Logo









ProLynx Inc.

ProLynx Inc.

Private
Emeryville, CaliforniaHealthcare & Life Scienceshttps://prolynxinc.com/

Last Round

Series A

Dec 11, 2025

Total Funding Raised

$72.65M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

ProLynx Inc. is a biotechnology company developing a portfolio of ultra-long-acting medicines for obesity and related metabolic diseases using its proprietary half-life extension technology platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

drug deliverylinker technologyhalf-life extensionpharmacokinetic optimizationbiotech platformtherapeutic proteinsdrug conjugatescontrolled releasebiopharma licensingdrug delivery platformPK optimizationdrug formulationbiotech R&Ddrug delivery tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ProLynx Inc. Comparables

Compare ProLynx Inc. with similar companies based on industry and business-model similarity.

ProLynx Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Serina Therapeutics Inc
79%
InnoCore Pharmaceuticals
79%
Johnson & Johnson
76%

ProLynx Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 11, 2025
SeedSep 10, 2020
GrantJul 7, 2020
DebtApr 14, 2020
GrantNov 1, 2018
Grant
Sep 25, 2017

Key People

Founding team and executive leadership

Chris Boulton

Chief Executive Officer

Executive Team

ProLynx Inc. Investors

Notable investors and investment history

ProLynx Inc. investors
InvestorRounds
NIH RADxGrant
OrbiMedSeries A
5AM VenturesSeries A
Monograph CapitalSeries A
National Science FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2026

    Grew 15% QoQ, from 33 to 38 employees.

  • Jun 19, 2026

    Monthly visitors increased 1674% MoM, reaching 1.2K.

ProLynx Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ProLynx Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ProLynx Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersEmeryville, California
Employee Range38
Year Founded2009
Last FundingDec 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?